CN101428145A - 新型疫苗佐剂 - Google Patents
新型疫苗佐剂 Download PDFInfo
- Publication number
- CN101428145A CN101428145A CNA2007101651688A CN200710165168A CN101428145A CN 101428145 A CN101428145 A CN 101428145A CN A2007101651688 A CNA2007101651688 A CN A2007101651688A CN 200710165168 A CN200710165168 A CN 200710165168A CN 101428145 A CN101428145 A CN 101428145A
- Authority
- CN
- China
- Prior art keywords
- adjuvant
- vaccine
- nanoparticle
- immunostimulant
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012646 vaccine adjuvant Substances 0.000 title description 4
- 229940124931 vaccine adjuvant Drugs 0.000 title description 4
- 239000002671 adjuvant Substances 0.000 claims abstract description 175
- 229960005486 vaccine Drugs 0.000 claims abstract description 49
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000839 emulsion Substances 0.000 claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims description 45
- 102000036639 antigens Human genes 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 239000003921 oil Substances 0.000 claims description 39
- 235000019198 oils Nutrition 0.000 claims description 39
- 239000002105 nanoparticle Substances 0.000 claims description 27
- 230000003308 immunostimulating effect Effects 0.000 claims description 23
- 229960001438 immunostimulant agent Drugs 0.000 claims description 18
- 239000003022 immunostimulating agent Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000002480 mineral oil Substances 0.000 claims description 10
- 235000010446 mineral oil Nutrition 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 208000009305 pseudorabies Diseases 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 235000013311 vegetables Nutrition 0.000 claims description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 4
- 241000204031 Mycoplasma Species 0.000 claims description 4
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 4
- 235000006533 astragalus Nutrition 0.000 claims description 4
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 4
- 229960003321 baicalin Drugs 0.000 claims description 4
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 210000004233 talus Anatomy 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- 208000002979 Influenza in Birds Diseases 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008168 almond oil Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 206010064097 avian influenza Diseases 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 229960003971 influenza vaccine Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 35
- 239000002245 particle Substances 0.000 abstract description 4
- 238000007086 side reaction Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000000091 immunopotentiator Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 230000001900 immune effect Effects 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000010241 blood sampling Methods 0.000 description 7
- 230000009849 deactivation Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 5
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001138504 Mycoplasma bovis Species 0.000 description 3
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 235000021053 average weight gain Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002766 immunoenhancing effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
组别 | IgG平均值 | 阳性率 |
无佐剂组 | 0.304 | 6/10 |
本发明佐剂组1 | 0.924 | 10/10 |
氢氧化铝比较佐剂组 | 0.654 | 9/10 |
免疫刺激复合物比较佐剂组 | 0.697 | 10/10 |
非免疫对照组 | 0.024 | 0/10 |
阳性对照孔 | 0.310 | 2/2 |
空白孔 | 0.021 | 0/4 |
成份(ml) | 佐剂1组 | 佐剂2组 | ISA206组 | 白油组 |
Lasota抗原 | 28 | 28 | 28 | 28 |
10%甲醛 | 1 | 1 | 1 | 1 |
1%硫柳汞 | 1 | 1 | 1 | 1 |
佐剂 | 30 | 30 | 60 | 60 |
PBS | 30 | 30 | ||
终体积 | 90 | 90 | 90 | 90 |
分组 | 21天 | 42天 | 局部反应 |
佐剂1组 | 5.4 | 7.2 | 无损伤、吸收良 |
佐剂2组 | 5.2 | 6.6 | 无损伤、吸收良 |
ISA206组 | 6.9 | 6.1 | 无损伤、吸收良 |
白油苗组 | 8.0 | 8.0 | 轻微的炎症反应、吸收较差 |
组别 | 免疫前平均体重(g) | 免疫后42天平均体重(g) | 平均增重(g) |
佐剂1组 | 427 | 1061 | 634 |
佐剂2组 | 424 | 1136 | 712 |
ISA206组 | 422 | 922 | 500 |
白油苗组 | 425 | 894 | 469 |
成份(ml) | 佐剂1组 | 白油组 |
伪狂犬灭活抗原 | 7 | 7 |
佐剂 | 7 | 14 |
磷酸盐缓冲液 | 7 | 0 |
终体积 | 21 | 21 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101651688A CN101428145B (zh) | 2007-11-05 | 2007-11-05 | 新型疫苗佐剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101651688A CN101428145B (zh) | 2007-11-05 | 2007-11-05 | 新型疫苗佐剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101428145A true CN101428145A (zh) | 2009-05-13 |
CN101428145B CN101428145B (zh) | 2013-01-02 |
Family
ID=40643913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101651688A Active CN101428145B (zh) | 2007-11-05 | 2007-11-05 | 新型疫苗佐剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101428145B (zh) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293743A (zh) * | 2010-06-24 | 2011-12-28 | 辽宁成大生物股份有限公司 | 一种脂质微球组合物 |
CN102327228A (zh) * | 2011-09-26 | 2012-01-25 | 黑龙江大学 | 壳聚糖新城疫疫苗纳米粒的制备方法 |
CN102764435A (zh) * | 2012-08-03 | 2012-11-07 | 中国农业科学院兰州兽医研究所 | 一种猪用亚洲i型口蹄疫病毒灭活疫苗佐剂及制备方法 |
CN101731506B (zh) * | 2009-12-15 | 2013-01-09 | 白万军 | 蜂胶林蛙卵磷脂胶囊保健食品 |
CN103202809A (zh) * | 2013-01-05 | 2013-07-17 | 安徽农业大学 | 11s大豆抗原蛋白注射液及其制备方法 |
CN104147599A (zh) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | 一种疫苗佐剂、其制备方法及应用 |
CN104208664A (zh) * | 2013-05-30 | 2014-12-17 | 上海医药工业研究院 | 一种鼻用疫苗组合物液体制剂及其制备方法 |
CN104473872A (zh) * | 2014-12-11 | 2015-04-01 | 浙江大学 | 植物多糖油乳剂及其制备方法和用途 |
CN104587457A (zh) * | 2015-01-13 | 2015-05-06 | 广东海大畜牧兽医研究院有限公司 | 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法 |
CN105031645A (zh) * | 2015-07-09 | 2015-11-11 | 宁波荣安生物药业有限公司 | 一种人用狂犬病疫苗及其制备方法 |
CN105169385A (zh) * | 2015-07-13 | 2015-12-23 | 国家纳米科学中心 | 一种用于疫苗的非载体佐剂、其制备方法及应用 |
WO2016027135A1 (es) * | 2014-08-22 | 2016-02-25 | Idisa Innovacion, S.A. De C.V. | VACUNA EMULSIONADA PARA OBTENER FORMULACIONES DE INMUNOGLOBULINAS IgY CONCENTRADAS; PROCESOS Y USOS DE LAS MISMAS. |
CN105688207A (zh) * | 2016-03-11 | 2016-06-22 | 中牧实业股份有限公司 | 一种动物疫苗用复合佐剂及其应用 |
CN106310249A (zh) * | 2015-06-14 | 2017-01-11 | 黑龙江省百洲生物工程有限公司 | 一种油乳剂灭活苗新型佐剂的制备及应用方法 |
CN106421775A (zh) * | 2015-08-12 | 2017-02-22 | 普莱柯生物工程股份有限公司 | 一种疫苗用佐剂及含该佐剂的疫苗组合物和其应用 |
CN106511995A (zh) * | 2016-10-19 | 2017-03-22 | 天津佐沐生物科技有限公司 | 一种水包油包水型疫苗佐剂及其应用 |
CN107441485A (zh) * | 2016-06-01 | 2017-12-08 | 普莱柯生物工程股份有限公司 | 一种复合疫苗佐剂组合物 |
CN108187040A (zh) * | 2018-01-10 | 2018-06-22 | 杭州洪晟生物技术股份有限公司 | 一种疫苗佐剂及其制备方法 |
CN108578688A (zh) * | 2018-04-03 | 2018-09-28 | 武汉轻工大学 | 多重纳米乳疫苗佐剂的制备方法 |
CN111057738A (zh) * | 2020-01-02 | 2020-04-24 | 浙江大学 | C2c12细胞在疫苗佐剂机制研究中的用途和研究分析方法 |
WO2022253193A1 (zh) * | 2021-05-30 | 2022-12-08 | 中国科学院上海药物研究所 | 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用 |
CN115590873A (zh) * | 2022-10-31 | 2023-01-13 | 河南省农业科学院动物免疫学重点实验室(Cn) | 黄芩苷在制备抗伪狂犬病毒药物中的应用 |
CN117281899A (zh) * | 2022-06-24 | 2023-12-26 | 江苏瑞科生物技术股份有限公司 | 一种佐剂系统及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU769539B2 (en) * | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
CN100398151C (zh) * | 2005-02-18 | 2008-07-02 | 浙江大学 | 人参皂甙纳米微粒及其制备方法和用途 |
AR054822A1 (es) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
-
2007
- 2007-11-05 CN CN2007101651688A patent/CN101428145B/zh active Active
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101731506B (zh) * | 2009-12-15 | 2013-01-09 | 白万军 | 蜂胶林蛙卵磷脂胶囊保健食品 |
CN102293743B (zh) * | 2010-06-24 | 2013-09-18 | 辽宁成大生物股份有限公司 | 一种脂质微球组合物 |
CN102293743A (zh) * | 2010-06-24 | 2011-12-28 | 辽宁成大生物股份有限公司 | 一种脂质微球组合物 |
CN102327228A (zh) * | 2011-09-26 | 2012-01-25 | 黑龙江大学 | 壳聚糖新城疫疫苗纳米粒的制备方法 |
CN102764435A (zh) * | 2012-08-03 | 2012-11-07 | 中国农业科学院兰州兽医研究所 | 一种猪用亚洲i型口蹄疫病毒灭活疫苗佐剂及制备方法 |
CN102764435B (zh) * | 2012-08-03 | 2014-04-16 | 中国农业科学院兰州兽医研究所 | 一种猪用亚洲i型口蹄疫病毒灭活疫苗佐剂及制备方法 |
CN103202809A (zh) * | 2013-01-05 | 2013-07-17 | 安徽农业大学 | 11s大豆抗原蛋白注射液及其制备方法 |
CN104208664A (zh) * | 2013-05-30 | 2014-12-17 | 上海医药工业研究院 | 一种鼻用疫苗组合物液体制剂及其制备方法 |
CN104208664B (zh) * | 2013-05-30 | 2017-03-29 | 上海医药工业研究院 | 一种鼻用疫苗组合物液体制剂及其制备方法 |
CN104147599B (zh) * | 2014-06-24 | 2017-03-01 | 华中科技大学 | 一种疫苗佐剂、其制备方法及应用 |
CN104147599A (zh) * | 2014-06-24 | 2014-11-19 | 华中科技大学 | 一种疫苗佐剂、其制备方法及应用 |
US10583189B2 (en) * | 2014-08-22 | 2020-03-10 | Investigacion Aplicada, S.A. De C.V. | Emulsified vaccine to obtain formulations of concentrated IgY immunoglobulins; processes and uses for the same |
CN107073098A (zh) * | 2014-08-22 | 2017-08-18 | 研究应用股份公司 | 获得浓缩IgY免疫球蛋白调配物的乳化疫苗、其方法及用途 |
WO2016027135A1 (es) * | 2014-08-22 | 2016-02-25 | Idisa Innovacion, S.A. De C.V. | VACUNA EMULSIONADA PARA OBTENER FORMULACIONES DE INMUNOGLOBULINAS IgY CONCENTRADAS; PROCESOS Y USOS DE LAS MISMAS. |
RU2689386C2 (ru) * | 2014-08-22 | 2019-05-28 | Инвестигасьон Апликада, С.А. Де С.В. | ЭМУЛЬГИРОВАННАЯ ВАКЦИНА ДЛЯ ПОЛУЧЕНИЯ КОНЦЕНТРИРОВАННЫХ КОМПОЗИЦИЙ ИММУНОГЛОБУЛИНОВ IgY; СПОСОБЫ И ИХ ПРИМЕНЕНИЯ |
CN107073098B (zh) * | 2014-08-22 | 2021-03-30 | 研究应用股份公司 | 获得浓缩IgY免疫球蛋白调配物的乳化疫苗、其方法及用途 |
US20170258899A1 (en) * | 2014-08-22 | 2017-09-14 | Investiacion Aplicada, S.A. DE C.V. | Emulsified vaccine to obtain formulations of concentrated igy immunoglobulins; processes and uses for the same |
CN104473872A (zh) * | 2014-12-11 | 2015-04-01 | 浙江大学 | 植物多糖油乳剂及其制备方法和用途 |
CN104473872B (zh) * | 2014-12-11 | 2017-09-26 | 杭州眺旺生物科技有限公司 | 植物多糖油乳剂及其制备方法和用途 |
CN104587457A (zh) * | 2015-01-13 | 2015-05-06 | 广东海大畜牧兽医研究院有限公司 | 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法 |
CN106310249A (zh) * | 2015-06-14 | 2017-01-11 | 黑龙江省百洲生物工程有限公司 | 一种油乳剂灭活苗新型佐剂的制备及应用方法 |
CN105031645A (zh) * | 2015-07-09 | 2015-11-11 | 宁波荣安生物药业有限公司 | 一种人用狂犬病疫苗及其制备方法 |
CN105031645B (zh) * | 2015-07-09 | 2018-08-17 | 宁波荣安生物药业有限公司 | 一种人用狂犬病疫苗及其制备方法 |
CN105169385A (zh) * | 2015-07-13 | 2015-12-23 | 国家纳米科学中心 | 一种用于疫苗的非载体佐剂、其制备方法及应用 |
CN105169385B (zh) * | 2015-07-13 | 2019-03-12 | 国家纳米科学中心 | 一种用于疫苗的非载体佐剂、其制备方法及应用 |
CN106421775A (zh) * | 2015-08-12 | 2017-02-22 | 普莱柯生物工程股份有限公司 | 一种疫苗用佐剂及含该佐剂的疫苗组合物和其应用 |
CN105688207A (zh) * | 2016-03-11 | 2016-06-22 | 中牧实业股份有限公司 | 一种动物疫苗用复合佐剂及其应用 |
CN105688207B (zh) * | 2016-03-11 | 2019-06-07 | 中牧实业股份有限公司 | 一种动物疫苗用复合佐剂及其应用 |
CN107441485B (zh) * | 2016-06-01 | 2021-07-23 | 普莱柯生物工程股份有限公司 | 一种复合疫苗佐剂组合物 |
CN107441485A (zh) * | 2016-06-01 | 2017-12-08 | 普莱柯生物工程股份有限公司 | 一种复合疫苗佐剂组合物 |
CN106511995A (zh) * | 2016-10-19 | 2017-03-22 | 天津佐沐生物科技有限公司 | 一种水包油包水型疫苗佐剂及其应用 |
CN108187040A (zh) * | 2018-01-10 | 2018-06-22 | 杭州洪晟生物技术股份有限公司 | 一种疫苗佐剂及其制备方法 |
CN108187040B (zh) * | 2018-01-10 | 2021-11-09 | 浙江洪晟生物科技股份有限公司 | 一种疫苗佐剂及其制备方法 |
CN108578688A (zh) * | 2018-04-03 | 2018-09-28 | 武汉轻工大学 | 多重纳米乳疫苗佐剂的制备方法 |
CN108578688B (zh) * | 2018-04-03 | 2022-02-11 | 武汉轻工大学 | 多重纳米乳疫苗佐剂的制备方法 |
CN111057738A (zh) * | 2020-01-02 | 2020-04-24 | 浙江大学 | C2c12细胞在疫苗佐剂机制研究中的用途和研究分析方法 |
WO2022253193A1 (zh) * | 2021-05-30 | 2022-12-08 | 中国科学院上海药物研究所 | 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用 |
CN117281899A (zh) * | 2022-06-24 | 2023-12-26 | 江苏瑞科生物技术股份有限公司 | 一种佐剂系统及其制备方法和应用 |
CN115590873A (zh) * | 2022-10-31 | 2023-01-13 | 河南省农业科学院动物免疫学重点实验室(Cn) | 黄芩苷在制备抗伪狂犬病毒药物中的应用 |
CN115590873B (zh) * | 2022-10-31 | 2023-08-11 | 河南省农业科学院动物免疫学重点实验室 | 黄芩苷在制备抗伪狂犬病毒药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101428145B (zh) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101428145B (zh) | 新型疫苗佐剂 | |
Kallon et al. | Astragalus polysaccharide enhances immunity and inhibits H9N2 avian influenza virus in vitro and in vivo | |
CN1126568C (zh) | 用于疫苗中的佐剂 | |
CN109666609B (zh) | 一种赤红球菌发酵方法及其作为佐剂在动物疫苗中的应用 | |
Gerdts | Adjuvants for veterinary vaccines--types and modes of action | |
CN111671894B (zh) | 一种基于铝佐剂的疫苗递送系统及其制备方法 | |
CN104055736A (zh) | 包封纳米铝的载体及其应用 | |
CN102086447A (zh) | 鸭病毒性肝炎毒株及灭活疫苗 | |
CN107073097A (zh) | 双佐剂疫苗组合物、制备和用途 | |
CN101123982B (zh) | 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂 | |
CN104258389B (zh) | 一种疫苗组合物及其制备方法和应用 | |
AU2013351213B2 (en) | Vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida | |
CN104531625A (zh) | 一种鸭病毒性肝炎的灭活疫苗及其制备方法与应用 | |
CN103083659A (zh) | 新型无油佐剂制备方法及用途 | |
CN112089834B (zh) | 基于氧化石墨烯的茯苓多糖纳米佐剂及佐剂/抗原共递送疫苗的制备与应用 | |
AU769390B2 (en) | Vaccine composition | |
CN106798920B (zh) | 一种复合免疫佐剂及其制备方法和应用 | |
CN111701018A (zh) | 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统 | |
CN102764435A (zh) | 一种猪用亚洲i型口蹄疫病毒灭活疫苗佐剂及制备方法 | |
JPH07506565A (ja) | アジュバントとしてのアセマンナンを含有するワクチン | |
CN106924730B (zh) | 猪伪狂犬病毒芦荟胶纳米乳佐剂灭活苗及其制备方法 | |
CN105903034B (zh) | 一种香菇多糖修饰的碳纳米管及其制备方法与应用 | |
CN111888468B (zh) | 一种免疫水佐剂及其制备方法 | |
CN1414861A (zh) | 通过皮肤途径接种诱导粘膜免疫性 | |
CN105749278A (zh) | 一种抗猪伪狂犬病的组合物、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090513 Assignee: BEIJING HUAXIA XINGYANG BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Assignor: BEIJING CENTRE BIOLOGY Co.,Ltd. Contract record no.: 2015990000368 Denomination of invention: New vaccine adjuvant Granted publication date: 20130102 License type: Exclusive License Record date: 20150525 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100081 room two, zone 12, 312 South Main Street, Haidian District, Beijing, Zhongguancun Patentee after: BEIJING CENTRE BIOLOGY Co.,Ltd. Address before: 100081 room two, zone 12, 312 South Main Street, Haidian District, Beijing, Zhongguancun Patentee before: BEIJING CENTRE BIOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231129 Address after: 102600 No.44 Yongda Road, Daxing biomedical industrial base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: BEIJING HUAXIA XINGYANG BIOLOGICAL SCIENCE & TECHNOLOGY CO.,LTD. Address before: 100081 room two, zone 12, 312 South Main Street, Haidian District, Beijing, Zhongguancun Patentee before: BEIJING CENTRE BIOLOGY Co.,Ltd. |